Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.42 AUD | 0.00% | +9.09% | +21.74% |
04:04am | Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial | MT |
Apr. 30 | Canaccord Starts Immutep at Buy, Price Target is AU$1.00 | MT |
Sales 2024 * | 4.14M 2.71M | Sales 2025 * | 17.82M 11.66M | Capitalization | 499M 327M |
---|---|---|---|---|---|
Net income 2024 * | -44M -28.79M | Net income 2025 * | -42M -27.48M | EV / Sales 2024 * | 102 x |
Net cash position 2024 * | 75.11M 49.15M | Net cash position 2025 * | 61.67M 40.35M | EV / Sales 2025 * | 24.6 x |
P/E ratio 2024 * |
-11.1
x | P/E ratio 2025 * |
-11.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.19% |
1 week | +9.09% | ||
Current month | +10.53% | ||
1 month | +7.69% | ||
3 months | +20.00% | ||
6 months | +31.25% | ||
Current year | +21.74% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
David Fang
DFI | Director of Finance/CFO | - | 18-02-28 |
Florian Vogl
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Russell Howard
CHM | Chairman | 74 | 13-05-07 |
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
Anne Anderson
BRD | Director/Board Member | - | Feb. 13 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 0.42 | 0.00% | 2 653 859 |
24-05-01 | 0.42 | -2.33% | 1,850,123 |
24-04-30 | 0.43 | -3.37% | 3,428,321 |
24-04-29 | 0.445 | +5.95% | 2,651,345 |
24-04-26 | 0.42 | -6.67% | 4,968,700 |
Delayed Quote Australian S.E., May 02, 2024 at 02:10 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.74% | 324M | |
+0.67% | 42.4B | |
+46.40% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- IMM Stock